Evotec (ETR:EVT) Given a €43.00 Price Target at Royal Bank of Canada

Royal Bank of Canada set a €43.00 ($44.79) price target on Evotec (ETR:EVTGet Rating) in a research note issued to investors on Tuesday, Borsen Zeitung reports.

A number of other research analysts have also recently commented on EVT. Deutsche Bank Aktiengesellschaft set a €39.00 ($40.63) target price on Evotec in a research note on Monday, February 7th. Jefferies Financial Group set a €45.00 ($46.88) target price on Evotec in a research note on Wednesday, May 11th. Deutsche Bank Rese… set a €33.00 ($34.38) target price on Evotec in a research note on Thursday, May 12th. Morgan Stanley set a €42.00 ($43.75) price objective on Evotec in a research note on Friday, April 29th. Finally, Warburg Research set a €43.00 ($44.79) price objective on Evotec in a research note on Wednesday, May 11th.

EVT opened at €24.87 ($25.91) on Tuesday. The stock has a market cap of $4.40 billion and a PE ratio of 19.20. The company has a quick ratio of 3.19, a current ratio of 3.39 and a debt-to-equity ratio of 37.23. The business has a 50 day moving average of €25.53 and a 200-day moving average of €32.76. Evotec has a 52 week low of €20.24 ($21.08) and a 52 week high of €45.83 ($47.74).

About Evotec (Get Rating)

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health.

Further Reading

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.